Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of estrogen receptor positive breast cancer recurrence, but many women do not respond to therapy. Observational studies nested in clinical trial populations suggest that overexpression or nuclear localization of p21-activated kinas...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Acta Oncol
Main Authors: Ahern, Thomas P., Cronin-Fenton, Deirdre P., Lash, Timothy L., Sørensen, Henrik Toft, Ording, Anne Gulbech, Hamilton-Dutoit, Stephen J., Hellberg, Ylva
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943575/
https://ncbi.nlm.nih.gov/pubmed/27056567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2016.1150606
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki